However, J54 can still mediate suppression in vivo of pNEK1 and pYAP, and consequently, PD-L1, which is known to be upregulated upon prolonged ENZ treatment, likely resulting in the suppression of anti-tumor rejection mechanisms in immunocompetent individuals. Here, CD274 is linked to neoplasm.